Isolation of Bacterial Bloodstream Infections in Patients with Systemic Lupus Erythematosus

Alaauldeen Alsaedy; Kumarss  Amini

doi:10.69923/zz2fc132

Authors

Alaauldeen Alsaedy Diyala university Author https://orcid.org/0009-0008-4120-3441
Kumarss Amini Islamic Azad University Author https://orcid.org/0000-0002-6419-3417

DOI:

https://doi.org/10.69923/zz2fc132

Keywords:

Systemic lupus, erythematosus, Bloodstream infection

Abstract

Patients with systemic lupus erythematosus (SLE) are at great risk of bacterial infection because of immune system dysregulation and immunosuppressive treatment. Urinary tract and bloodstream infections are some of the most frequent complications, with high morbidity. The objective of this study was to determine the etiological agents defined and associated with urine and blood samples of patients with SLE and characterize them. A total of 110 urine and 8 blood samples were taken from patients with SLE who appeared at the hospital between March and August 2024. Cultures were handled according to standard microbiological methods, and bacterial strains were identified using Gram staining, biochemistry techniques, and VITEK $4 automated equipment. Blood samples: Gram-positive had a marginal predominance (50%), and Escherichia coli 3 (37.5%) was the commonest isolate, followed by Staphylococcus aureus 2 (25%), K pneumoniae 1 (12.5%), P aeruginosa 1 (12.5%), and Enterococcus faecalis 1 (12.5%). Conclusion: The epidemiology of both UTIs and BSIs, whether about Gram status or species, is mixed, with Escherichia coli and Staphylococcus aureus as the most common overall isolates among SLE patients. Prompt identification and optimal antibiotic treatment are important for minimizing morbidity and preventing major complications in this immunocompromised population.

Downloads

Download data is not yet available.

Author Biographies

Alaauldeen Alsaedy, Diyala university

Alauldeen Sadeq Khalaf is an assistant lecturer and holds a master in the Department of Biology, College of Education for Pure Sciences, University of Diyala, Diyala, Iraq. alaauldeen7468@uodiyala.edu.iq
Kumarss Amini, Islamic Azad University

Kumarss Amini Full professor of microbiology, Department of Microbiology, Sav. C., Islamic Azad University, Saveh, IranKumarss@iau.ac.ir3

References

[1] G. C. Tsokos, "Autoimmunity and organ damage in systemic lupus erythematosus," Nat. Immunol., vol. 21, no. 6, pp. 605–614, Jun. 2020, doi: 10.1038/s41590-020-0677-6.

[2] A. L. F. Kunzler and G. C. Tsokos, "Infections in patients with systemic lupus erythematosus: The contribution of primary immune defects versus treatment-induced immunosuppression," Eur. J. Rheumatol., vol. 10, no. 4, pp. 148–158, Oct. 2023, doi: 10.5152/eurjrheum.2023.23068.

[3] M. Natesan, B. Ganesh, A. Narasingam, and R. M. Ragavan, "Report of multidrug resistant bloodstream bacterial infections in systemic lupus erythematosus patients in Southern India," Braz. J. Infect. Dis., vol. 24, no. 5, Sep./Oct. 2020, doi: 10.1016/j.bjid.2020.07.005.

[4] Í. Rúa-Figueroa, F. López-Longo, V. Del Campo, M. Galindo-Izquierdo, et al., "Bacteremia in systemic lupus erythematosus patients from RELESSER: risk factors, clinical and microbiological characteristics and outcomes," J. Rheumatol., Apr. 2019, doi: 10.3899/jrheum.180882.

[5] M. H. Kim, S. R. Choi, and J. W. Park, "Risk of bloodstream infection in patients with systemic lupus erythematosus exposed to prolonged medium-to-high-dose glucocorticoids," Lupus, 2023, doi: 10.1177/09612033231160731.

[6] C. C. Mok, C. L. Kwok, and L. Y. Ho, "Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China," Rheumatology, vol. 59, no. 9, pp. 2732–2739, 2020, doi: 10.1093/rheumatology/keaa020.

[7] D. Martin-Iglesias, D. Paredes-Ruiz, and G. Ruiz-Irastorza, "Use of glucocorticoids in SLE: A clinical approach," Mediterr. J. Rheumatol., vol. 35, suppl. 2, pp. 342–353, 2024.

[8] O. N. Pamuk, M. S. Ali, and S. Hasni, "Development of systemic lupus erythematosus in patients with immune thrombocytopenic purpura: A systematic meta-analysis," Autoimmun. Rev., vol. 22, no. 4, Art. no. 103297, Feb. 2023, doi: 10.1016/j.autrev.2023.103297.

[9] C. C. Mok and C. S. Lau, "Pathogenesis of systemic Lupus erythematosus," J. Clin. Pathol., vol. 56, pp. 481–490, 2003.

[10] M. Mosca et al., "Brief report: How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria," Arthritis Rheumatol., vol. 71, pp. 91–98, 2019. doi: 10.1002/art.40674. Epub 2018 Nov 26.

[11] S. Mukkera et al., "Systemic lupus erythematosus-associated serositis managed with intravenous belimumab: A case report," Cureus, vol. 14, Art. no. e22639, 2022. doi: 10.7759/cureus.22639.

[12] S. B. Mahmood and Z. Abou Zahr, "Systemic lupus erythematosus triggered by trimethoprim-sulfamethoxazole," Scand. J. Rheumatol., vol. 49, pp. 507–508, 2020. doi: 10.1080/03009742.2020.1719543.